PolyPid

We are PolyPid! A late-stage biopharmaceutical company aiming to improve surgical outcomes. $PYPD #RightWhereCareBegins

[PolyPid @PolyPidLtd]

$PYPD PolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀

Read the Full Press Release 👉 https://t.co/hO9NOIIAPg

[PolyPid @PolyPidLtd]

$PYPD PolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor Conference

Read the Full News Release 👉 https://t.co/ulHpq5sEiU

[PolyPid @PolyPidLtd]

Key highlights from $PYPD Q1 2026 call:
⚡ U.S. Commercial Partnership Discussions in Late Stages
⚡ Initiated NDA Submission to the FDA under Rolling Review
⚡ Advancing EU Regulatory Submission

Full PR here: https://t.co/UT53feSDfp

[PolyPid @PolyPidLtd]

$PYPD PolyPid Provides Corporate Update and Reports First Quarter 2026 Financial Results

Read the Full News Release 👉 https://t.co/60OneNlpsE

[PolyPid @PolyPidLtd]

$PYPD PolyPid to Report First Quarter 2026 Financial Results and Operational Highlights on May 13, 2026

Read the Full News Release 👉 https://t.co/g7CxatCGBc

[PolyPid @PolyPidLtd]

$PYPD PolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual Meeting

Read the Full News Release 👉 https://t.co/HxNaX7HlHr

[PolyPid @PolyPidLtd]

$PYPD PolyPid to Present New Phase 3 SHIELD II Data Demonstrating DPLEX₁₀₀ Sustained Local Release at ESCMID Global 2026

Read the Full Press Release 👉 https://t.co/wjd7snPF8B

[PolyPid @PolyPidLtd]

$PYPD PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA

Read the Full News Release 👉 https://t.co/X9mwtB2EVh

[PolyPid @PolyPidLtd]

$PYPD PolyPid Receives PDUFA Fee Waiver from FDA for D-PLEX₁₀₀’s New Drug Application

Read the Full News Release 👉 https://t.co/R1bV1amo8e

[B2i Digital @b2idigital]

As Marketing Partner for the 38th Annual @ROTHCapital Partners Conference, @b2idigital is spotlighting presenting company @PolyPidLtd (NASDAQ: $PYPD).

PolyPid Ltd. (Nasdaq: PYPD) is an innovative biopharmaceutical company dedicated to elevating treatment effectiveness, right where care begins. The Company develops long-acting, controlled-release drugs designed to deliver therapy precisely at the site of care, addressing critical unmet medical needs across a wide and diverse pipeline spanning surgical care, metabolic diseases, and beyond. PolyPid’s lead product, D-PLEX₁₀₀, successfully met its primary and all key secondary endpoints in the landmark Phase 3 SHIELD II trial for the prevention of surgical site infections. Guided by a commitment to precision and innovation, PolyPid is redefining how therapies perform and raise the standard of patient care.

Presenting company website: https://t.co/0LlUgWEM2u

B2i Digital Featured Conference details: https://t.co/uYRKzxTx6W

The 38th Annual ROTH Conference is an invitation-only corporate access event connecting executive teams from roughly 500 growth companies with institutional investors and other market participants. The conference is held at The Ritz-Carlton Laguna Niguel in Dana Point, California, March 22 to 24, 2026. It is one of the largest small-cap investor conferences in the United States.

Conference features include:

• 1-on-1 and small group management-investor meetings
• Analyst-selected fireside chats, industry keynotes, and panels
• ROTH Consumer Private Company Day & Emerging Brand Showcase
• Inaugural Engineering & Construction Day (NEW)
• ROTH/CAF Charity Ride, Spin, Yoga, Pickleball & Golf (Sunday)
• Networking receptions and live evening entertainment

B2i Digital, The Capital Markets Matchmaker℠, will leverage its network of 1.5 million+ investors to help enhance visibility for presenting companies, aligned with our mantra, From Marketing to Meetings℠.

Registration is required and subject to approval by ROTH: https://t.co/FJsY4IfbVW

Credit to the team at ROTH for hosting this premier event: Byron Roth, Aaron Gurewitz, Isabel Mattson-Pain, Nazan Akdeniz, Otilia "Charo" Montano, Grace Deller, Amanda McAdams, Harry Fong, Matthew Day, David Farina.

David Shapiro and Joseph Azizo from B2i Digital will also be in attendance and look forward to seeing you there.

ROTH is a relationship-driven investment bank focused on serving growth companies and their investors across capital raising, equity research, sales and trading, M&A advisory, and corporate access. For more information, visit https://t.co/f7LaejqxRB.

B2i Digital is not a broker-dealer or investment adviser. This is for general information only and is not an offer to buy or sell any security.

[PolyPid @PolyPidLtd]

@the_yaniv @Yotmaz @TalMorgenstern Hi @the_yaniv - in addition to successful phase 3 in antibiotics we also have great animal data in RNA delivery - let us collaborate

[PolyPid @PolyPidLtd]

Tune in for the latest podcast episode of Smart Money Circle with $PYPD CEO, Dikla Czaczkes Akselbrad. Thank you @adamsarhan for hosting us and being a great interviewer
👉 Watch & listen here:
https://t.co/spmqOWZSgm

[PolyPid @PolyPidLtd]

$PYPD PolyPid Announces Participation in Upcoming Investor Conferences

Read the Full News Release 👉 https://t.co/aUUF509Dob

[PolyPid @PolyPidLtd]

$PYPD Q4 Investor Call is happening today.
What a year it has been and more is coming.

See our PR to learn more about timing of FDA submission, new branding and new technology platform:
https://t.co/JsHZ1l1pPV

[PolyPid @PolyPidLtd]

$PYPD PolyPid to Report Fourth Quarter 2025 Financial Results and Operational Highlights on February 11, 2026

Read the Full News Release 👉 https://t.co/ASCnQOf3YM

[PolyPid @PolyPidLtd]

Proud to see $PYPD included in @Bloomberg’s coverage of Israeli Wartime Tech Economy.

Here is a link to segment: https://t.co/hhj1kX8k8F

#RightWhereCareBegins #IsraeliInnovation #Biotech #LifeSciences #HealthcareInnovation

[PolyPid @PolyPidLtd]

We’re excited to unveil $PYPD new visual brand identity - a look that reflects an important moment in our journey, evolving from a research-driven organization to a commercial-stage company

[PolyPid @PolyPidLtd]

We are happy to participate in the inaugural Global BioInnovation Forum during #JPMWeek.
Jan 13, 2026 | Virtual

Register: https://t.co/Egk48ZoTX7

$PYPD

[PolyPid @PolyPidLtd]

$PYPD PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors

Read the Full News Release 👉 https://t.co/DL01OVDkTR

[PolyPid @PolyPidLtd]

Join us tomorrow (Wednesday) at @ROTHCapital's virtual KOL event where internationally recognized colorectal surgeon Steven D. Wexner will discuss the clinical & economic burden of SSIs and the therapeutic potential of D-PLEX₁₀₀.

https://t.co/SZHfOSxYHL $PYPD